# Spruce Biosciences, Inc.: financial statements, quarterly

SPRB · Nasdaq · CIK 1683553 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sprb.md) · [Financials](/companies/sprb/financials.md) · [Filings](/companies/sprb/filings.md) · [Insiders](/companies/sprb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sprb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.1](/filings/0000950170-24-124479.md) | [2.9 d](/filings/0000950170-25-053945.md) | [2.0](/filings/0000950170-25-064463.md) | [1.6](/filings/0000950170-25-108888.md) | [0.6](/filings/0001193125-25-274234.md) | [0.7 d](/filings/0001193125-26-097558.md) | [0.0](/filings/0000950170-25-064463.md) | [0.0](/filings/0000950170-25-108888.md) | [0.0](/filings/0001193125-25-274234.md) | [0.0 d](/filings/0001193125-26-097558.md) | not reported | not reported |
| Research and development | $m | [13.5](/filings/0000950170-24-124479.md) | [11.1 d](/filings/0000950170-25-053945.md) | [10.3](/filings/0000950170-25-064463.md) | [8.1](/filings/0000950170-25-108888.md) | [6.6](/filings/0001193125-25-274234.md) | [21.5 d](/filings/0001193125-26-097558.md) | [10.8](/filings/0001193125-26-221605.md) | [(0.4)](/filings/0001193125-26-345876.md) | [5.0](/filings/0001193125-25-274234.md) | [4.1 d](/filings/0001193125-26-097558.md) | [7.6](/filings/0001193125-26-221605.md) | [12.2](/filings/0001193125-26-345876.md) |
| Operating income | $m | [(13.7)](/filings/0000950170-24-124479.md) | [(11.2) d](/filings/0000950170-25-053945.md) | [(12.6)](/filings/0000950170-25-064463.md) | [(10.0)](/filings/0000950170-25-108888.md) | [(9.4)](/filings/0001193125-25-274234.md) | [(24.1) d](/filings/0001193125-26-097558.md) | [(14.5)](/filings/0001193125-26-221605.md) | [(2.7)](/filings/0001193125-26-345876.md) | [(8.2)](/filings/0001193125-25-274234.md) | [(11.1) d](/filings/0001193125-26-097558.md) | [(12.0)](/filings/0001193125-26-221605.md) | [(16.5)](/filings/0001193125-26-345876.md) |
| Interest expense | $m | [0.1](/filings/0000950170-24-124479.md) | [0.1 d](/filings/0000950170-25-053945.md) | [0.1](/filings/0000950170-25-064463.md) | [0.1](/filings/0000950170-25-108888.md) | [0.1](/filings/0001193125-25-274234.md) | [0.1 d](/filings/0001193125-26-097558.md) | [0.0](/filings/0001193125-26-221605.md) | [0.0](/filings/0001193125-26-345876.md) | [0.0](/filings/0001193125-25-274234.md) | [0.0 d](/filings/0001193125-26-097558.md) | [0.7](/filings/0001193125-26-221605.md) | [1.1](/filings/0001193125-26-345876.md) |
| Net income | $m | [(12.4)](/filings/0000950170-24-124479.md) | [(10.0) d](/filings/0000950170-25-053945.md) | [(11.6)](/filings/0000950170-25-064463.md) | [(9.2)](/filings/0000950170-25-108888.md) | [(8.7)](/filings/0001193125-25-274234.md) | [(23.6) d](/filings/0001193125-26-097558.md) | [(14.0)](/filings/0001193125-26-221605.md) | [(2.1)](/filings/0001193125-26-345876.md) | [(8.2)](/filings/0001193125-25-274234.md) | [(14.6) d](/filings/0001193125-26-097558.md) | [(12.3)](/filings/0001193125-26-221605.md) | [(16.2)](/filings/0001193125-26-345876.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0000950170-24-124479.md) | not reported | [(0.28)](/filings/0000950170-25-064463.md) | [(16.73)](/filings/0000950170-25-108888.md) | [(15.75)](/filings/0001193125-25-274234.md) | not reported | [(23.95)](/filings/0001193125-26-221605.md) | [(3.50)](/filings/0001193125-26-345876.md) | [(14.58)](/filings/0001193125-25-274234.md) | not reported | [(8.94)](/filings/0001193125-26-221605.md) | [(6.68)](/filings/0001193125-26-345876.md) |
| Basic EPS | $ per share | [(0.30)](/filings/0000950170-24-124479.md) | not reported | [(0.28)](/filings/0000950170-25-064463.md) | [(16.73)](/filings/0000950170-25-108888.md) | [(15.75)](/filings/0001193125-25-274234.md) | not reported | [(23.95)](/filings/0001193125-26-221605.md) | [(3.50)](/filings/0001193125-26-345876.md) | [(14.58)](/filings/0001193125-25-274234.md) | not reported | [(8.94)](/filings/0001193125-26-221605.md) | [(6.68)](/filings/0001193125-26-345876.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [98.8](/filings/0000950170-24-124479.md) | [96.3](/filings/0000950170-25-053945.md) | [81.2](/filings/0000950170-25-064463.md) | [69.7](/filings/0000950170-25-108888.md) | [60.1](/filings/0001193125-25-274234.md) | [38.8](/filings/0001193125-26-097558.md) | [25.6](/filings/0001193125-26-221605.md) | [16.4](/filings/0001193125-26-345876.md) | [10.7](/filings/0001193125-25-274234.md) | [48.9](/filings/0001193125-26-345876.md) | [54.1](/filings/0001193125-26-221605.md) | [96.3](/filings/0001193125-26-345876.md) |
| Current assets | $m | [111](/filings/0000950170-23-062997.md) | [102](/filings/0000950170-25-053945.md) | [85.9](/filings/0000950170-24-058657.md) | [73.9](/filings/0000950170-24-095461.md) | [63.6](/filings/0000950170-24-124479.md) | [44.2](/filings/0001193125-26-097558.md) | [30.6](/filings/0000950170-25-064463.md) | [21.0](/filings/0000950170-25-108888.md) | [14.5](/filings/0001193125-25-274234.md) | [52.1](/filings/0001193125-26-345876.md) | [55.0](/filings/0001193125-26-221605.md) | [101](/filings/0001193125-26-345876.md) |
| Total assets | $m | [113](/filings/0000950170-23-062997.md) | [104](/filings/0000950170-25-053945.md) | [87.5](/filings/0000950170-24-058657.md) | [75.5](/filings/0000950170-24-095461.md) | [65.1](/filings/0000950170-24-124479.md) | [45.2](/filings/0001193125-26-097558.md) | [31.6](/filings/0000950170-25-064463.md) | [21.8](/filings/0000950170-25-108888.md) | [15.3](/filings/0001193125-25-274234.md) | [53.0](/filings/0001193125-26-345876.md) | [56.2](/filings/0001193125-26-221605.md) | [103](/filings/0001193125-26-345876.md) |
| Current liabilities | $m | [24.2](/filings/0000950170-23-062997.md) | [24.5](/filings/0000950170-25-053945.md) | [18.4](/filings/0000950170-24-058657.md) | [14.3](/filings/0000950170-24-095461.md) | [11.9](/filings/0000950170-24-124479.md) | [15.2](/filings/0001193125-26-097558.md) | [15.7](/filings/0000950170-25-064463.md) | [8.1](/filings/0000950170-25-108888.md) | [9.4](/filings/0001193125-25-274234.md) | [10.1](/filings/0001193125-26-345876.md) | [11.8](/filings/0001193125-26-221605.md) | [11.0](/filings/0001193125-26-345876.md) |
| Total liabilities | $m | [27.6](/filings/0000950170-23-062997.md) | [27.4](/filings/0000950170-25-053945.md) | [20.9](/filings/0000950170-24-058657.md) | [16.4](/filings/0000950170-24-095461.md) | [13.5](/filings/0000950170-24-124479.md) | [16.4](/filings/0001193125-26-097558.md) | [16.3](/filings/0000950170-25-064463.md) | [8.6](/filings/0000950170-25-108888.md) | [9.9](/filings/0001193125-25-274234.md) | [10.5](/filings/0001193125-26-345876.md) | [21.5](/filings/0001193125-26-221605.md) | [19.1](/filings/0001193125-26-345876.md) |
| Long-term debt | $m | [2.1](/filings/0000950170-23-062997.md) | [1.7](/filings/0000950170-25-053945.md) | [1.3](/filings/0000950170-24-058657.md) | [0.9](/filings/0000950170-24-095461.md) | [0.5](/filings/0000950170-24-124479.md) | [0.1](/filings/0001193125-26-097558.md) | [0.0](/filings/0000950170-25-064463.md) | [0.0](/filings/0000950170-25-108888.md) | [0.0](/filings/0001193125-25-274234.md) | [0.0](/filings/0001193125-26-345876.md) | [5.5](/filings/0001193125-26-221605.md) | [4.6](/filings/0001193125-26-345876.md) |
| Current portion of debt | $m | [1.6](/filings/0000950170-23-062997.md) | [1.6](/filings/0000950170-25-053945.md) | [1.6](/filings/0000950170-24-058657.md) | [1.6](/filings/0000950170-24-095461.md) | [1.6](/filings/0000950170-24-124479.md) | [1.6](/filings/0001193125-26-097558.md) | [1.3](/filings/0000950170-25-064463.md) | [0.9](/filings/0000950170-25-108888.md) | [0.5](/filings/0001193125-25-274234.md) | [0.0](/filings/0001193125-26-345876.md) | [1.0](/filings/0001193125-26-221605.md) | [2.5](/filings/0001193125-26-345876.md) |
| Shareholders' equity | $m | [85.4](/filings/0000950170-24-124479.md) | [76.5](/filings/0001193125-26-097558.md) | [66.6](/filings/0000950170-25-108888.md) | [59.2](/filings/0001193125-25-274234.md) | [51.6](/filings/0001193125-25-274234.md) | [28.8](/filings/0001193125-26-345876.md) | [15.3](/filings/0001193125-26-345876.md) | [13.2](/filings/0001193125-26-345876.md) | [5.4](/filings/0001193125-25-274234.md) | [42.5](/filings/0001193125-26-345876.md) | [34.6](/filings/0001193125-26-345876.md) | [83.7](/filings/0001193125-26-345876.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.3) d](/filings/0000950170-24-124479.md) | [(11.2) d](/filings/0000950170-25-053945.md) | [(15.0)](/filings/0000950170-25-064463.md) | [(11.1) d](/filings/0000950170-25-108888.md) | [(9.2) d](/filings/0001193125-25-274234.md) | [(20.7) d](/filings/0001193125-26-097558.md) | [(12.7)](/filings/0001193125-26-221605.md) | [(8.8) d](/filings/0001193125-26-345876.md) | [(5.3) d](/filings/0001193125-25-274234.md) | [(6.5) d](/filings/0001193125-26-097558.md) | [(8.7)](/filings/0001193125-26-221605.md) | [(22.1) d](/filings/0001193125-26-345876.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-124479.md) | [0.0 d](/filings/0000950170-25-053945.md) | not reported | not reported | not reported | [0.0 d](/filings/0000950170-25-053945.md) | [0.0](/filings/0001193125-26-221605.md) | [0.0 d](/filings/0001193125-26-345876.md) | not reported | not reported | [0.0](/filings/0001193125-26-221605.md) | [0.1 d](/filings/0001193125-26-345876.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.6](/filings/0000950170-23-062997.md) | [31.9](/filings/0000950170-24-058657.md) | [40.5](/filings/0000950170-24-095461.md) | [40.7](/filings/0000950170-24-124479.md) | [41.1](/filings/0000950170-25-064463.md) | [0.5](/filings/0000950170-25-108888.md) | [0.6](/filings/0001193125-25-274234.md) | [0.6](/filings/0001193125-26-221605.md) | [0.6](/filings/0001193125-26-345876.md) | [0.6](/filings/0001193125-25-274234.md) | [1.4](/filings/0001193125-26-221605.md) | [2.4](/filings/0001193125-26-345876.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,874,013 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-345876.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.